$189.2 M

AGLE Mkt cap, 26-Oct-2018
Aeglea Biotherapeutics Net income (Q2, 2018)-17.5 M
Aeglea Biotherapeutics EBIT (Q2, 2018)-17.9 M
Aeglea Biotherapeutics Cash, 30-Jun-201820.6 M

Aeglea Biotherapeutics Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

18.1m22.8m

General and administrative expense

8.4m10.1m

Operating expense total

26.5m32.9m

EBIT

(21.9m)(27.7m)

Interest income

244.0k482.0k

Net Income

(21.7m)(27.2m)

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

R&D expense

3.6m4.4m5.4m4.9m5.8m6.9m16.0m

General and administrative expense

1.8m2.4m2.1m2.4m2.4m2.9m5.8m

Operating expense total

5.4m6.9m7.5m7.3m8.2m9.8m21.8m

EBIT

(4.6m)(5.5m)(6.3m)(6.3m)(6.7m)(8.2m)(17.9m)

Interest income

26.0k74.0k72.0k95.0k100.0k143.0k406.0k

Net Income

(4.5m)(5.4m)(6.2m)(6.2m)(6.6m)(8.1m)(17.5m)

Aeglea Biotherapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

47.7m12.8m

Accounts Receivable

164.2m

Inventories

1.7m

Current Assets

66.4m55.0m

PP&E

599.0k854.0k

Total Assets

67.1m56.1m

Accounts Payable

168.0k389.0k

Current Liabilities

4.0m5.6m

Total Liabilities

4.1m5.7m

Additional Paid-in Capital

108.2m123.0m

Retained Earnings

(45.3m)(72.5m)

Total Equity

63.0m50.3m

Financial Leverage

1.1 x1.1 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

24.0m70.6m49.5m16.8m26.9m10.8m20.6m

Current Assets

35.2m76.9m71.7m60.3m66.2m48.8m78.9m

PP&E

321.0k377.0k342.0k822.0k802.0k810.0k776.0k

Total Assets

35.5m77.3m72.1m61.3m67.1m49.8m79.7m

Accounts Payable

509.0k348.0k523.0k267.0k634.0k763.0k952.0k

Current Liabilities

3.8m3.4m3.8m4.0m4.4m5.8m6.2m

Total Liabilities

3.8m3.4m3.9m4.1m4.5m5.9m6.3m

Additional Paid-in Capital

1.5m107.5m108.0m108.7m120.8m124.6m163.5m

Retained Earnings

(28.1m)(33.6m)(39.8m)(51.5m)(58.2m)(80.6m)(90.0m)

Total Equity

(26.6m)73.9m68.2m57.2m62.6m43.9m73.4m

Financial Leverage

-1.3 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x

Aeglea Biotherapeutics Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(21.7m)(27.2m)

Depreciation and Amortization

132.0k249.0k

Accounts Receivable

(43.6k)

Inventories

(96.1k)

Accounts Payable

(8.0k)164.0k

Cash From Operating Activities

(18.8m)(24.6m)

Purchases of PP&E

(212.0k)(619.0k)

Cash From Investing Activities

(12.1m)(22.5m)

Cash From Financing Activities

49.4m12.2m

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(4.5m)(10.0m)(16.2m)(6.2m)(8.1m)(17.5m)

Depreciation and Amortization

29.0k62.0k96.0k52.0k70.0k145.0k

Accounts Payable

261.0k172.0k347.0k95.0k396.0k579.0k

Cash From Operating Activities

(4.0m)(8.6m)(14.5m)(5.4m)(7.4m)(16.5m)

Purchases of PP&E

(2.0k)(91.0k)(91.0k)(271.0k)(83.0k)(118.0k)

Cash From Investing Activities

(1.2m)660.0k(14.6m)(25.6m)4.7m(14.5m)

Cash From Financing Activities

(98.0k)49.3m49.4m96.0k688.0k38.8m

Aeglea Biotherapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Aeglea Biotherapeutics Operating Metrics

FY, 2016

Nonclinical Development

3

Phase 1/2 Trials Products

1

Phase Approved

1

Phase I Trials Products

2
Report incorrect company information

Aeglea Biotherapeutics Employee Rating

3.52 votes
Culture & Values
4.0
Work/Life Balance
4.0
Senior Management
3.0
Salary & Benefits
4.0
Career Opportunities
4.0
Source